HUTCHMED (China) Limited

NASDAQ:HCM

Drug Manufacturers - Specialty & Generic

Healthcare
$13.99 +1.58%

+$0.16 today

Market cap
$2.44B
Beta
0.37
P/E (TTM)
46.2
EPS (TTM)
$0.05
52W Low $10.01High $19.50

Volume 0.04M

Average 0.04M

HCM Sales of Investments

Cash received from selling or redeeming investments.

HUTCHMED (China) LimitedNASDAQ: HCM

Sales of Investments · Q2 FY2025 · quarter ended Jun 2025

Sales of investments outflow shrinks to $0

Q2 FY2025 sales of investments was $0, compared with $995.3M a year earlier. Trailing-twelve-month sales of investments was $0. Over 3 fiscal years it compounded at +21.8% a year.

Context

  • Sales of investments amounted to 499.0% of revenue in FY2025, up 218.2 pp from a year earlier.
  • Sales of investments increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly sales of investments holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2025
$0— QoQ
Last fiscal yearDec 2025
$2.74B+55.1% YoY
LTMJun 2025
$0-100.0% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+55.1%——
3-year CAGR+21.8%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
2.74B USD
Year-over-year change
+55.1%
4-year CAGR
+31.4%

Sales of Investments vs competitors

How HCM compares with its peers on the latest reported figures

  • Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -100.0% is the 7th highest of 8, against a peer median of -19.6%.
  • Sales of investments amounts to 0.0% of revenue for HCM, versus a peer median of 41.1%.
HCM Competitors
Sales of Investments for HCM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€10.31B EUR-19.6%+189.9%389.9%
GMABGenmab A/SLTM Jun 2026$2.03B USD—-28.7%49.1%
LEGNLegend Biotech CorporationLTM Sep 2026$1.02B USD-79.1%+105.5%75.2%
RCUSArcus Biosciences, Inc.LTM Jun 2026$958M USD-17.3%+11.0%818.8%
EXELExelixis, Inc.LTM Jul 2026$805.24M USD-19.9%-1.3%33.1%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$656.41M USD-13.2%+44.4%291.4%
INCYIncyte CorporationLTM Jun 2026$284.53M USD+36.8%+53.2%4.9%
HCMHUTCHMED (China) LimitedLTM Jun 2025$0 USD-100.0%+21.8%0.0%
ZLABZai Lab LimitedLTM Jun 2026$0 USD-100.0%-22.3%0.0%
ANLAdlai Nortye Ltd.LTM Jun 2024$0 USD—-61.4%0.0%
AAPGAscentage Pharma Group InternationalFY2025CN¥0 CNY——0.0%
Peer median (excluding HCM) —-19.6%+11.0%41.1%

Competitors are the stored peer set for HCM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(167.04M)(360.39M)100.78M37.73M458.12M
Depreciation & Amortization7.19M8.66M8.21M12.34M13.34M
Deferred Income Tax(115.14M)0(102.76M)00
Stock-Based Compensation41.99M30.59M36.6M21.61M15.29M
Change in Working Capital32.46M58.7M71.15M(62.17M)(61.02M)
Accounts Receivables(35.63M)(14.45M)(21.34M)(41.57M)28.94M
Inventory(16M)(21.21M)4.14M(772K)9.57M
Accounts Payables9.57M29.94M(32.54M)03.02M
Other Working Capital74.53M64.04M120.89M(19.82M)(102.55M)
Other Non-Cash Items(3.68M)(6.17M)105.28M(9.01M)(490.56M)
Operating Cash Flow(204.22M)(268.6M)219.26M497K(64.83M)
Capital Expenditures(16.76M)(36.66M)(32.61M)(17.93M)(14.19M)
Acquisitions (Net)159.12M324K(2.99M)028.07K
Purchases of Investments(1.37B)(1.2B)(1.63B)(1.85B)(2.75B)
Sales of Investments921.36M1.52B1.37B1.77B2.74B
Other Investing Activities930K16.49M29.5M1.28M0
Investing Cash Flow(306.32M)296.59M(291.14M)(96.06M)(29.49M)
Debt Repayment(579.77K)(9.17M)61.71M5.61M6.27M
Common Stock Issued717.32M174K5.09M790K1.58M
Common Stock Repurchased(27.31M)(48.08M)(9.07M)(36.06M)0
Dividends Paid(99.74M)(87.44M)000
Other Financing Activities60.34M61.75M(9.07M)(1M)0
Financing Cash Flow650.03M(82.76M)48.66M(30.67M)7.86M
Effect of Forex Changes2.43M(9.49M)(6.47M)(3.4M)3.83M
Net Change in Cash141.91M(64.26M)(29.69M)(129.63M)(82.63M)
Free Cash Flow(220.98M)(305.26M)186.65M(17.44M)(79.01M)

HUTCHMED (China) Limited

NASDAQ:HCM

Intrinsic Alpha fair value

Locked

Current Price

$13.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.